Claus Bo Svendsen

Claus Bo Svendsen, CEO of Forward Pharma, has a long and impressive history in the medical and pharmaceutical industries. Claus has worked as a medical analyst and global medical director for companies such as Novo Nordisk and Nordic Biotech Advisors. In these roles, they were responsible for evaluating potential drug candidates, conducting due diligence analysis, and predicting market trends. Claus has also been responsible for heading up Global Medical Affairs for liraglutide 3.0 mg for obesity (Saxenda) at Novo Nordisk. In their current role as CEO of Forward Pharma, they are responsible for the company's overall strategy and direction. Under their leadership, Forward Pharma has become a leading player in the development of innovative treatments for rare diseases.

Claus Bo Svendsen is a medical doctor who has also earned an Executive Certificate in General Management from Copenhagen Business School. Claus also has a PhD in Chronic inflammation, Pulmonary Medicine, and Microbiology from University of Copenhagen. In addition, they have certification from Whitehall Online Training in GMP (Good Manufacturing Practice) Annex 13 certificate and ICH GCP (Good Clinical Practice) E6 R2 certificate. Claus is also licensed to practice as a physician in Denmark and Sweden.